The firm's average rating is Buy from 2 analysts. Macroaxis provides advice on Curevac NV to complement and cross-verify current
analyst consensus on Curevac NV. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon.
The successful prediction of CureVac NV
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as CureVac NV, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of CureVac NV based on CureVac NV hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to CureVac NV's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to CureVac NV's related companies.
Use Technical Analysis to project CureVac expected Price
CureVac NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of CureVac NV technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of CureVac NV trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...CureVac NV Gross Profit
CureVac NV Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CureVac NV previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CureVac NV Gross Profit growth over the last 10 years. Please check CureVac NV's
gross profit and other
fundamental indicators for more details.
Breaking down CureVac NV Indicators
The current price rise of Curevac NV could raise concerns from investors as the firm it trading at a share price of
86.00 on
461,700 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
December. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.94. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Curevac NV partners.
Deferred Revenue Breakdown
Curevac NV Deferred Revenue is increasing over the years with slightly volatile fluctuation. Ongoing Deferred Revenue is projected to grow to about 80.3
M this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Curevac NV Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 73.52 Million
| 2010 | 70.36 Million |
| 2019 | 73.52 Million |
| 2020 | 80.35 Million |
Our take on today Curevac NV rise
Current market risk adjusted performance is at 1.3. Curevac NV shows above-average downside volatility for the selected time horizon. We advise investors to inspect Curevac NV further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Curevac NV future alpha.
Our Bottom Line On Curevac NV
Whereas some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Curevac NV may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Curevac nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Curevac NV.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of CureVac NV. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
